Permira is selling Australia's I-Med Radiology Network, which recently entered the U.S. by acquiring StatRad, to Hong Kong-based multinational conglomerate Jardine Matheson.
The Bedford, Massachusetts-based company has reportedly been approached about a possible acquisition by competitor Curium Pharma, Bloomberg reported May 22.
Last week hospitals owned by three big health systems filed suit against CVS Health. The trio filed separately, but all accuse the corporation of robbing them of funds they’re owed through the federal 340B drug pricing program.
The change would represent an imperfect but, in many cases, perfectly appropriate way to oversee the technology without crimping its capabilities. So say three thought leaders who are close watchers of medical ethics and technologies.
TAVR procedures with a higher implant depth are associated with certain clinical benefits after one year, according to a new study of data from more than 600 patients.
Edwards Lifesciences asked the U.S. Federal Trade Commission (FTC) this week to dismiss the complaint against the company's acquisition of JenaValve this week. A healthcare market analysis firm also said the FTC actions will likely impact the timing of an FDA clearance of the Trilogy heart valve.
A new generation of AI-native researchers is leading the way in the war on cancer. This next crop of scientists is AI-native, interdisciplinary—and comfortable challenging assumptions.
The New York-based safety net hospital has accused former CEO Megan Ryan of impropriety that includes paying out $3.5 million to herself and 12 other executives. She denies the allegations, and claims she is a whistleblower for fraud committed by the state.
The roots of medicine are in the promotion of human welfare, aka humanitarianism. Healthcare AI can either degrade or reinforce this heritage. Who picks the path?
Permira is selling Australia's I-Med Radiology Network, which recently entered the U.S. by acquiring StatRad, to Hong Kong-based multinational conglomerate Jardine Matheson.
The Bedford, Massachusetts-based company has reportedly been approached about a possible acquisition by competitor Curium Pharma, Bloomberg reported May 22.
